PhysQuiz on ASCO GU: Renal Carcinoma
Are you caught up on breaking trial results released at ASCO GU? Test your knowledge on our Renal...
Read MoreMay 10, 2021
Are you caught up on breaking trial results released at ASCO GU? Test your knowledge on our Renal...
Read MoreApr 27, 2021
Although the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated improved progression-free survival (PFS) and overall survival...
Read MoreMar 19, 2021
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...
Read MoreMar 19, 2021
Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101 In the phase III JAVELIN Renal 101...
Read MoreMar 19, 2021
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...
Read More